Immuneering (IMRX) Analyst & Key Data

Analyst Consensus

Buy5 analysts

Buy

Updated Sep 12, 2026

Total Analysts5

Buy

7

Hold

4

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$4.27

Median Target+298.13%

$17.00

Potential upside vs current price

DCF Value-34.35%

$2.80

Potential downside vs current price

Current Stock Price

$4.27

Median Target+298.13%

$17.00

Potential upside vs current price

DCF Value-34.35%

$2.80

Potential downside vs current price

Analyst Consensus

Buy5 analysts

Buy

Updated Sep 12, 2026

Total Analysts5

Buy

7

Hold

4

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$4.27

Median Target+298.13%

$17.00

Potential upside vs current price

DCF Value-34.35%

$2.80

Potential downside vs current price

Current Stock Price

$4.27

Median Target+298.13%

$17.00

Potential upside vs current price

DCF Value-34.35%

$2.80

Potential downside vs current price

Immuneering Corporation